MicroRNAs and Cardiovascular Disease

Author(s): Zhiguo Wang

DOI: 10.2174/978160805184711001010121

Circulating miRNAs as Biomarkers for Cardiac Disease

Pp: 121-126 (6)

Buy Chapters

* (Excluding Mailing and Handling)

  • * (Excluding Mailing and Handling)

Abstract

SHS investigation development is considered from the geographical and historical viewpoint. 3 stages are described. Within Stage 1 the work was carried out in the Department of the Institute of Chemical Physics in Chernogolovka where the scientific discovery had been made. At Stage 2 the interest to SHS arose in different cities and towns of the former USSR. Within Stage 3 SHS entered the international scene. Now SHS processes and products are being studied in more than 50 countries.

Abstract

This chapter aims to discuss recent advances of circulating miRNAs as new and promising biomarkers for cardiac disease. The elucidation of miRomes between diseased and normal cardiovascular tissues or between different cardiovascular disease types, stages and grades, gives the chance to identify the miRNAs most probably involved in cardiovascular disease and to establish new diagnostic and prognostic markers. Recent findings suggest that circulating miRNAs may be plasma biomarkers for the diagnosis of lung, colorectal, and prostate cancers. These findings have been also tested for cardiovascular disease. miRNAs are present in human plasma in a remarkably stable form that is protected from endogenous RNase activity. The levels of miRNAs in serum are reproducible and consistent among individuals of the same species. In particular, blood miR-1, miR-133, miR- 208a and miR-499 have been suggested as biomarkers of acute myocardial infarction; miR-208, miR-423-5p and some other miRNAs in the circulation are correlated with heart failure; and miR-122, miR-124 and miR-133 may be used to predict cerebral artery occlusion stroke.

Recommended Chapters

We recommend

Favorable 70-S: Investigation Branching Arrow

Authors:Bentham Science Books